Study evaluating efficacy of Sirolimus-Coated Balloon against Drug-eluting Stent completes patient enrollment
Cleveland: An Italy-based research foundation, the Lodi has announced the completion of patient enrolment for a trial evaluating the safety and effectiveness of
Sirolimus-Coated Balloon
(SCB) in comparison with the Drug-eluting Stents.
The trial has enrolled a total of 1,832 patients from Europe, Asia, and South America and designed to evaluate the safety and effectiveness of the MagicTouch Sirolimus-Coated Balloon (SCB) in comparison with the Everolimus-Eluting Stent (EES) in patients with De-Novo
Coronary Artery Disease
.
'After 3 and half years, we were able to complete the enrolment in
TRANSFORM II trial
, a study that involved 52 centers across 3 continents and will test this Sirolimus DCB with the most studied and used DES, in a daily patient population,' said Dr Bernardo Cortese, the Study Chairman.
The head-to-head comparison is undertaken to determine whether drug-coated balloon technology can be widely adopted for primary treatment of small coronary lesions—which currently accounts for nearly 80 per cent of all
Percutaneous Coronary Interventions
.
Developed by
Concept Medical
in delivers sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall.
The device has obtained
Breakthrough Device Designation
from the US FDA for the treatment of small coronary vessels and in-stent restenosis.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
4 hours ago
- New Indian Express
Pharma dept refuses to name 30 docs penalised for Paris, Monaco trip
NEW DELHI: Despite a Centre-appointed panel under the Department of Pharmaceuticals (DoP) reprimanding AbbVie Healthcare India Pvt Ltd for violating the uniform code for pharmaceutical marketing practice (UCPMP) by sponsoring trips to Monaco and Paris, in France, for 30 doctors worth Rs 1.91 crore, the department has refused to share the names of the 'offending' doctors against whom action was to be initiated. Revealing the names would involve disclosing personal information of individuals and it was not in public interest, the department said, defending its decision. Notably, the refusal to share the names of the doctors by the DoP under the Ministry of Chemicals and Fertilisers comes five months after activist Dr K V Babu filed an RTI over the matter. Moreover, the DoP is yet to share the names of the doctors with the National Medical Commission (NMC), which was asked by the Apex Committee for Pharma Marketing Practices to take action against the '30 offending healthcare professionals as per Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002' in its order on December 23, 2024. As per the norms, the doctor's licenses can be suspended if found guilty of violating the code of ethics. In its order, the committee also directed the Central Board of Direct Taxes to evaluate the tax liability of AbbVie Healthcare India Pvt Ltd, a subsidiary of US-based pharmaceutical company AbbVie Inc, for unethical marketing practices, along with the 30 doctors, and to take action in accordance with the provisions of the Income Tax Act, 1961.
United News of India
6 hours ago
- United News of India
AP: Serum Institute launches nationwide HPV-Cancer public awareness campaign
Visakhapatnam, June 13 (UNI) : The 'Conquer HPV & Cancer Conclave 2025' was launched here on Friday as part of a nationwide public health initiative by Pune-based Serum Institute of India Pvt. Ltd, part of Cyrus Poonawalla Group is a global leader in vaccine manufacturing. India continues to face a significant burden of HPV-related diseases, particularly cervical cancer, which remains the second most common cancer among women in the country. According to the ICO/IARC Information Centre on HPV and Cancer (2023), India reports over 1.23 lakh new cervical cancer cases and more than 77,000 related deaths annually. Apart from this up to 90 percent of anal cancers & 63 percent of penile cancers are associated with HPV. At the Visakhapatnam event, a panel of medical specialists engaged in an in-depth discussion about the public health implications of HPV. The panel included Dr. Sunanda Rani Gutta – Director & Chief Consultant Gynaecologist, Nikitha Hospital, Visakhapatnam; Dr. Redla Vidya Rama – Prof. of Obstetrics & Gynecology, Andhra Medical College and King George Hospital; Dr. Sai Sunil Kishore Manem – Chief Neonatologist, Medicover Hospital, Vizag. Associate Professor MIMS Medical College, Vizianagaram and Dr. Buddha Murali Santosh – MBBS, DNB, fellowship in Neonatology. Gold medalist. Neonatologist and Pediatrician at Motherly Women and Children Hospital, Vizag The session was moderated by Dr. Vani Isukapalli – Superintendent, King George Hospital, Visakhapatnam. President-IMA, Visakhapatnam. Together, they highlighted the pressing need for awareness, the importance of reaching both adolescents and parents, and the role of healthcare providers in guiding preventive care. The speakers emphasized that HPV is not limited to cervical cancer alone. It is also associated with cancers of the vulva, vagina, anus, penis, and oropharynx, affecting both men and women. With peak HPV infection occurring between ages 15 to 25, early awareness and timely preventive action are essential. With an affordable HPV vaccine now available, it has become still more easier to protect every individual from HPV associated cancers. 'Through these conclaves held across the country, we aim to increase understanding of Human Papillomavirus (HPV) and its link to cervical and other cancers,' said Parag Deshmukh, Executive Director, Serum Institute of India. 'By bringing together medical experts, healthcare workers, and community members, the forum encourages open dialogue and practical steps toward early detection and prevention,' he said. The Visakhapatnam conclave concluded with an open dialogue involving audience members, reinforcing the broader goal of the campaign: to reduce the burden of preventable cancers through informed decision-making and community engagement. The initiative will continue in cities across the country in the coming months, creating platforms for credible voices in healthcare to educate and empower the public. UNI KNR SSP
Hindustan Times
7 hours ago
- Hindustan Times
Serum, DNDi to develop affordable dengue treatment
Serum Institute of India (SII) on Friday signed a memorandum of understanding (MoU) with not-for-profit medical research organisation Drugs for Neglected Diseases initiative (DNDi) to accelerate clinical development of a monoclonal antibody treatment for dengue that will be affordable and accessible in low-and middle-income countries (LMICs). SII and DNDi will develop a work plan to implement research and development, Phase 3 clinical trials, and access activities, along with a joint strategy to raise the necessary funds and resources. SII stated that it has already conducted pre-clinical studies and Phase 1 and 2 clinical trials that show the candidate is safe and effective. It is currently leading the Phase 3 clinical trial in India for licensure. The Pune-based company said a joint project team will be formed to advance clinical trials, with the goal of registering and deploying the dengue monoclonal antibody in India and other countries, provided the studies confirm its safety and efficacy.
